Human herpesvirus-8-related Kaposi's sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin.
The iatrogenic form of Kaposi's sarcoma (KS) is typically observed among transplant recipients, and the most appropriate therapeutic approach (usually including reduction of immunosuppression, specific chemotherapy, and/or administration of antiviral agents against human herpes virus-8) is still controversial. Available experiences on the effect of the anti-herpes viruses drug cidofovir provide conflicting results. Herein, we report the clinical, histological, and virological features of a liver transplant recipient successfully treated with a combined therapy of cidofovir and liposomal daunorubicin, associated with a reduction of the immunosuppressive regimen, for an advanced cutaneous and visceral KS.
Verucchi
G
G
Department of Clinical and Experimental Medicine, Section of Infectious Diseases, S. Orsola Hospital Alma Mater Studiorum University of Bologna, Italy.
Calza
L
L
Trevisani
F
F
Zambruni
A
A
Tadolini
M
M
Giuliani
R
R
Manfredi
R
R
Andreone
P
P
Chiodo
F
F
Bernardi
M
M
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D016867:Immunocompromised Host; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000821:virology; D019562:Viral Load; D014766:Viremia
D000903:Antibiotics, Antineoplastic; D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir; D003630:Daunorubicin